CytRx Corporation (CYTR)

0.29
0.01 5.36
OTC
Prev Close 0.28
Open 0.26
Day Low/High 0.26 / 0.29
52 Wk Low/High 0.26 / 0.97
Volume 19.62K
Exchange OTC
Shares Outstanding 33.64B
Market Cap 9.79M
Div & Yield N.A. (N.A)

CytRx Chief Executive Officer And Chief Medical Officer Discuss Corporate Strategy And Development Pipeline In Fireside Chat With Biotech Research Analyst

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company specializing in oncology, today announced that a “fireside chat” discussion among CytRx President and CEO Steven A.

CytRx To Receive $3.8 Million From Sale Of RXi Pharmaceuticals Common Stock

CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical company specializing in oncology, today announced that it has entered into a definitive agreement with RXi Pharmaceuticals Corporation (NASDAQ:RXII) under which RXi...

CytRx To Present At The Roth Capital Partners OC Growth Stock Conference

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company specializing in oncology, today announced that CytRx President and CEO Steven A.

CytRx To Present At The 12th Annual BIO CEO & Investor Conference

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company specializing in oncology, today announced that CytRx President and CEO Steven A.

SeaChange, Tenet: Early Volume Plays

SeaChange, Tenet: Early Volume Plays

Several stocks trading near $5 were poised to move on above-average volume during Thursday's session.

CytRx: FDA Lifts 2-year Hold On Arimoclomol Tests

CytRx: FDA Lifts 2-year Hold On Arimoclomol Tests

CytRx says FDA lifts 2-year suspension on development of treatment for Lou Gehrig's disease

Correction: CytRx FDA Letter

Correction: CytRx FDA Letter

Correction: CytRx FDA letter

CytRx Expects To File FDA Response In 4Q

CytRx Expects To File FDA Response In 4Q

CytRx expects to send response to FDA request on Lou Gehrig's disease drug program in 4Q

CytRx Rises On Preclinical Data For Stroke Drug

CytRx Rises On Preclinical Data For Stroke Drug

CytRx stock advances following positive animal testing data for drug candidate arimoclomol

Movers Roundup: Massey Energy, MannKind

Movers roundup: Massey Energy down on SCOTUS ruling, MannKind hits year high on insulin med

CytRx Rises On Analyst's 'Outperform' Rating

CytRx rises after analyst assigns top rating based on opportunities to partner drug candidates

Patience Pays

Watching the market can be unsettling as a recession looms, but the volatility can offer profitable opportunities.

Moving On

News that one of its clinical trials has been placed on hold by the FDA is a serious blow to this biotech name.

Stocks Under $10 Weekly Summary

We made a few adjustments to the model portfolio this week, including closing out one name and adding another.

Stocks Under $10 Weekly Summary

Downswings this week prompted us to add to two favorites and remove one underperformer from the model portfolio.

Stocks Under $10 Weekly Summary

We continue to make the volatility work for us by adjusting the model portfolio based on our expectations for 2008.

Building on a Sharp Discount

Shares of this biotech are suffering an irrational hit, but that opens the door to add more shares.

Adding on a Dip

Today's drop in this stock's price creates an attractive opportunity to add to the position.

Stocks Under $10 Weekly Summary

Opportunities in small-caps should keep expanding in the new year, as many stocks have already priced in a recession.

Stocks Under $10 Weekly Summary

We closed one model portfolio position this week and made a few other changes to take advantage of the heavy volatility.

Stocks Under $10 Weekly Summary

We made a few moves in the model portfolio this week, initiating one new position and adding to two others.

A Positive Announcement

The deal struck by a subsidiary of this biotech name succeeds in beefing up its intellectual property.

Stocks Under $10 Weekly Summary

During a very positive week for the model portfolio, we took some profits and changed a couple of our ratings.

Gains Provide Opportunity

With many of our model portfolio names seeing solid upside, it's a profitable time to make room for new positions.

Stocks Under $10 Weekly Summary

It was an active week for the model portfolio as we made several moves to take advantage of the current volatility.

A New Opportunity

This biotech name offers a lot of potential risks, and rewards. Here's why we are initiating a position.

Biotech Notebook: Nastech, Amgen, PDL BioPharma

Skeptics of Nastech's nasal spray have gotten their due.

Wednesday's Health Winners & Losers

Nastech Pharma rises.

Wednesday's Small-Cap Winners & Losers

Wednesday's Small-Cap Winners & Losers

Blockbuster climbs on an analyst upgrade.

Wednesday's Health Winners & Losers

Wednesday's Health Winners & Losers

Biogen climbs on news of a $3 billion share buyback.